Investigational drug · Phase 3
NP-G2-044
Also called: Prilukae
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Platinum-resistant Ovarian Cancer, Advanced or Metastatic Solid Tumor Malignancies.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "NP-G2-044"
First trial start
2021
Dec 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NP-G2-044", any sponsor or status.
Conditions studied
As listed on its trial records.
- Platinum-resistant Ovarian Cancer
- Advanced or Metastatic Solid Tumor Malignancies
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NP-G2-044" as an intervention, largest first.
- Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)Pivotal-lookingActive, not recruiting
Novita Pharmaceuticals, Inc.Industry
NCT07109414 · 380 participants (planned) · Start Dec 29, 2025 · Primary completion Oct 25, 2028
Drug: NP-G2-044; PLD · For: Platinum-resistant Ovarian Cancer
Sites: Phoenix, Arizona; Shreveport, Louisiana; Albuquerque, New Mexico · 6 sites in all
Novita Pharmaceuticals, Inc.Industry
NCT05023486 · 121 participants · Start Dec 7, 2021 · Primary completion Jun 30, 2026
Drug: NP-G2-044 Monotherapy; Anti-PD-1 Therapy and 1 more · For: Advanced or Metastatic Solid Tumor Malignancies
Sites: Scottsdale, Arizona; Tucson, Arizona; Little Rock, Arkansas · 18 sites in all
Novita Pharmaceuticals, Inc.Industry
NCT03199586 · 23 participants · Start Dec 21, 2017 · Primary completion May 7, 2020
Drug: NP-G2-044 · For: Breast Cancer; Pancreas Cancer; Prostate Cancer and 6 more
Sites: Scottsdale, Arizona; Duarte, California; New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- FSCN1 Promotes Rheumatoid Arthritis Progression via Inhibiting TRIM38-Mediated Ubiquitination of IGF2BP1 in Fibroblast-Like Synoviocytes.
Chen L, Wu J, Zhou T, et al. · Arthritis Rheumatol 2026
- Dual regulation of metabolism and immune contact by a self-reinforcing hydrogel enhances CAR-T-mediated residual tumor clearance and surveillance.
Yang N, Tao L, Hu X, et al. · J Control Release 2026
- Thymic stromal lymphopoietin promotes ozone-induced inflammation in the airway.
Tashiro H, Kurihara Y, Kuwahara Y, et al. · Am J Respir Cell Mol Biol 2026
- Low YTHDC1 Expression Upregulates FSCN1 to Promote Nuclear F-Actin Formation and Facilitate Double-strand DNA Breaks Repair in TMZ-Resistant Glioblastoma.
Yang M, Niu W, Wang Y, et al. · Adv Sci (Weinh) 2026
- FSCN1 induces subchondral bone sclerosis in osteoarthritis via modulating actin cytoskeleton dynamics and YAP signaling.
Xiao Y, Chen L, Chen D, et al. · Arthritis Res Ther 2026
- Fascin Inhibitor NP-G2-044 Decreases Cell Metastasis while Increases Overall Survival of Mice-bearing Lung Cancers.
Zhang ZH, Liu XY, Feng JP, et al. · Curr Mol Med 2025
Also in development for Platinum-resistant Ovarian Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- ZN-c3azenosertibPhase 34 trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma
- Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
- TaxanePhase 33 trials
AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer
- LorigerlimabMGD019Phase 22 trials
MacroGenics · Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
- TILT-123Ad5, 3-E2F-d24-hTNFa-IRES-hIL2Phase 21 trial
TILT Biotherapeutics Ltd. · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.